Tekla Life Sciences Investors
HQL · NYSE
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Market Cap | $423,166 | $352,826 | $350,784 | $504,601 |
| - Cash | $0 | $0 | $0 | $1 |
| + Debt | $0 | $0 | $11,092 | $1,342 |
| Enterprise Value | $423,166 | $352,826 | $361,875 | $505,942 |
| Revenue | $86,685 | $39,385 | $31,862 | $45,024 |
| % Growth | 120.1% | 23.6% | -29.2% | – |
| Gross Profit | $86,685 | $18,280 | $26,313 | $38,948 |
| % Margin | 100% | 46.4% | 82.6% | 86.5% |
| EBITDA | $87,217 | $49,952 | -$101,615 | $68,678 |
| % Margin | 100.6% | 126.8% | -318.9% | 152.5% |
| Net Income | $85,296 | $22,352 | -$104,603 | $64,531 |
| % Margin | 98.4% | 56.8% | -328.3% | 143.3% |
| EPS Diluted | 3.04 | 0.79 | -4.07 | 2.66 |
| % Growth | 284.8% | 119.4% | -253% | – |
| Operating Cash Flow | – | $0 | $0 | $0 |
| Capital Expenditures | – | $0 | $0 | $0 |
| Free Cash Flow | – | $0 | $0 | $0 |